|
AstraZeneca to supply Europe with up to 400 million doses of Oxford University's vaccine at no profit
|
13 June 2020 |
|
AstraZeneca takes next steps towards broad and equitable access to Oxford University's COVID-19 vaccine
|
05 June 2020 |
|
Calquence showed promising clinical improvement in majority of 19 hospitalised COVID-19 patients
|
05 June 2020 |
|
AstraZeneca advances response to global COVID-19 challenge as it receives first commitments for Oxford's potential new vaccine
|
22 May 2020 |
|
AstraZeneca and Oxford University announce landmark agreement for COVID-19 vaccine
|
30 April 2020 |
|
AstraZeneca and Saint Luke’s Mid America Heart Institute initiate Phase III DARE-19 trial with Farxiga in COVID-19 patients
|
23 April 2020 |
|
AstraZeneca initiates CALAVI clinical trial with Calquence against COVID-19
|
14 April 2020 |
|
AstraZeneca to donate 9 million face masks to support healthcare workers around the world in the fight against COVID-19
|
24 March 2020 |
|
AstraZeneca completes divestment agreement with Atnahs Pharma for established hypertension medicines
|
02 March 2020 |
|
AstraZeneca divests global rights to Movantik
|
25 February 2020 |